Tango Therapeutics Announces Executive Departure of Barbara Weber, M.D.

What Happened
Tango Therapeutics (TNGX) announced the departure of Barbara Weber, M.D., and filed a Form 8-K/A on August 7, 2026 to disclose the change. The company furnished a Separation Agreement between Tango and Dr. Weber dated August 6, 2026 (Exhibit 10.1) and a press release dated August 6, 2026 (Exhibit 99.1) under Regulation FD.

Key Details

• The company reported the departure under Item 5.02 (departure of certain officers) and provided Regulation FD disclosure under Item 7.01.
• Separation Agreement dated August 6, 2026 was filed as Exhibit 10.1.
• Press release announcing the departure dated August 6, 2026 was filed as Exhibit 99.1.
• The Form 8-K/A was filed August 7, 2026; the filing states no other disclosures in the original Form 8-K are being amended.

Why It Matters
Leadership changes can be material for investors because they may affect program leadership, clinical development priorities, and investor confidence. The filing includes the separation agreement and press release for details; investors should review those exhibits (and future filings) for any disclosed financial terms, transition plans, or impacts on operations.